Scancell Holdings (SCLP)

 

SCLP Share PerformanceMore

52 week high21.880 07/03/16
52 week low12.800 24/06/16
52 week change -3.875 (-21.23%)
4 week volume3,499,122 01/02/17

Media for (SCLP)

Presenter: Dr Richard Goodfellow
30/07/2015
Presenter: Dr Richard Goodfellow
01/06/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Scancell widens H1 pretax loss

Scancell has widened its H1 pretax loss to 2.1m, from a year-earlier loss of 1.4m, adding 2017 is set to be an important and bu...

Interim Results

RNS Number: 5212V Scancell Holdings Plc 31 January 2017 31 January 2017 Scancell Holdings Plc ("Scancell" or the "Company") Interim Results for the 6 months ended 31 October 2016 Strong progress continues across all clinical programmes; planning to start US SCIB1 Phase 2 combination study in H2 2017 Scancell Holdings plc, ('Scancell' or the 'Company') the develo...

Scancell in partnership to advance lung cancer clinical trials

Scancell Holdings, The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundati...

Partnership to Advance Lung Cancer Clinical Trials

RNS Number: 4154V Scancell Holdings Plc 30 January 2017 Addario Lung Cancer Medical Institute and Scancell Holdings PLC Form Partnership to Advance Lung Cancer Vaccine Clinical Trials Collaboration builds a world-class network to develop innovative treatment alternatives for lung cancer patients ( January 30, 2017) - The Addario Lung Cancer Medical Inst...

Research Update - Amendment

RNS Number: 1955T Scancell Holdings Plc 03 January 2017 This replaces the announcement number 0710T made on 3 January 2017 at 7:00am GMT due to the following amendment: In the quote by Dr Richard Goodfellow, "next year" is replaced by "in the second half of the year". All other details remain unchanged. The full amended text is shown below. 3 January...

Scancell Holdings issues research update

Scancell Holdings announces that the Clinical Study Report (CSR) on the SCIB1 Phase 1/2 clinical trial in patients with Stage...

Research Update

RNS Number: 0710T Scancell Holdings Plc 03 January 2017 3 January 2017 Scancell Holdings Plc ("Scancell" or the "Company") Final SCIB1 Phase 1/2 Clinical Study Report completed on schedule Report confirms robust survival in late stage melanoma patients SCIB1 Phase 2 combination study on track; IND expected to be filed in H1 2017 Scancell Holdings plc, ('Scanc...

World Immunotherapy Congress and Biotech and Money

RNS Number: 0187P Scancell Holdings Plc 14 November 2016 14 November 2016 Scancell Holdings Plc ("Scancell" or the "Company") Scancell to present at the World Immunotherapy Congress in Basel and at the Biotech and Money Inv$tival Showcase in London Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatm...

Fundamental DataMore

EPS-1.14
Dividend yield0 %

Equity Research (SCLP)

hardman & co
Scancell Holdings PLC
26/09/2016
Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high...

Latest discussion posts More

  • Re: The penny drops

    Since my last post here, the S P sat then at circa 15.63p {mid}.... Despite ALL the "Deals ANY DAY now' and other 'promises by the blind-faithers'.... S P now = ???. FUNDING ...
    21-Feb-2017
    kipngail
  • SCLP chart

    http://bonker99.com/charts
    6-Feb-2017
    Bonker
  • The penny drops

    Another month showing further losses for the blind faithers. The ASTUTE will 'pick their moment' whilst the overburdened... can't. Into October , with an S P of what ...
    1-Oct-2016
    kipngail

Users' HoldingsMore

Users who hold Scancell Holdings also hold..
LLOYDS GRP.19%
SIRIUS MINERALS15%
TESCO12%
ROYAL BANK SCOT11%
PREMAITHA11%

Codes & Symbols

ISINGB00B63D3314
SymbolsSCLP, LSE:SCLP, SCLP.L, SCLP:LN, LON:SCLP, XLON:SCLP